FDA – Page 3 – Discover Pharma

Welcome to Discover Pharma! Today is : April 22, 2026

FDA

Artificial Intelligence,Regulatory Affairs,Technology and platforms
FDA launches AI tool Elsa to boost internal efficiency and accelerate reviews
The US Food and Drug Administration (FDA) has unveiled Elsa, [...]

June 8, 2025
Artificial Intelligence,Technology and platforms,Women in Pharma
AI governance in pharmacovigilance: Marie Flanagan calls for safety-specific frameworks to safeguard patient risk
The integration of artificial intelligence into pharmacovigilance is prompting a [...]

June 2, 2025
Biologics & Biosimilars,Precision medicine,Regulatory Affairs
Protagonist and Takeda present VERIFY data on rusfertide showing strong results in polycythemia vera
Protagonist and Takeda have shared full 32-week results from the [...]

June 2, 2025
Drug Delivery & Formulation,Regulatory Affairs
FDA approves Khindivi oral solution for pediatric adrenal insufficiency
Eton Pharmaceuticals has received US regulatory approval for Khindivi, the [...]

May 29, 2025
Biologics & Biosimilars,Clinical Trials,Patient Centricity
Poolbeg receives FDA Orphan Drug Designation for POLB 001
Poolbeg Pharma has been granted Orphan Drug Designation (ODD) by [...]

May 27, 2025
Artificial Intelligence,Drug Development
FDA fast-tracks generative AI rollout following successful scientific review pilot
The US Food and Drug Administration (FDA) has announced plans [...]

May 14, 2025
Movers & Shakers
Highlander Health names Nicholaas Honig executive director, expanding institute’s vision for clinical innovation
April 30, 2025
Clinical Trials
Novadip’s ‘off-the-shelf’ spine fusion product shows early efficacy and safety in studies
April 24, 2025
Clinical Trials
Oculis completes enrollment in DIAMOND Phase 3 trials of OCS-01 for diabetic macular edema
June 4, 2025

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK